GPCR on Nasdaq

Structure Therapeutics Inc.

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerGPCR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSouth San Francisco, California1
  • Incorporated inCayman Islands2
  • Business address601 Gateway Blvd Suite 900, South San Francisco, Ca 940802
  • Filer categoryLarge accelerated filer2
  • Legal formOther

See how the biggest companies compare on our leaderboards

We are a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). These important receptors regulate numerous and diverse physiological and pathological processes. In fact, approximately one in every three marketed medicines targets GPCR-associated pathways for the treatment of various metabolic, cardiovascular and pulmonary disorders. By leveraging our world-class GPCR know-how, we are designing differentiated small molecule therapies to overcome the limitations of biologics and peptide therapies that target this family of receptors.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$176.6M in 2025+236% since 2022
-$200.0M-$150.0M-$100.0M-$50.0M02022: -$52.6M-$52.6M20222023: -$102.8M-$102.8M2023+96%2024: -$158.2M-$158.2M2024+54%2025: -$176.6M-$176.6M2025+12%
Net income45-$141.2M in 2025+175% since 2022
-$150.0M-$100.0M-$50.0M02022: -$51.3M-$51.3M20222023: -$89.6M-$89.6M2023+75%2024: -$122.5M-$122.5M2024+37%2025: -$141.2M-$141.2M2025+15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Research and development$225.3M$108.8M$70.1M
General and administrative$61.6M$49.4M$32.7M
Other license income-$100.0M
Gains on sale of non-financial assets-$10.2M
Total operating expenses$176.6M$158.2M$102.8M
Loss from operations-$176.6M-$158.2M-$102.8M
Interest and other income, net$35.9M$36.0M$13.4M
Loss before provision for income taxes-$140.7M-$122.2M-$89.4M
Provision for income taxes$515.0K$310.0K$236.0K
Net loss attributable to ordinary shareholders-$141.2M-$122.5M-$89.6M
Net loss per share, basic-$0.80-$0.78-$0.81
Net loss per share, diluted-$0.80-$0.78-$0.81
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic177.6M shares157.9M shares110.2M shares
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, diluted177.6M shares157.9M shares110.2M shares
Unrealized gain on investments, net$140.0K$393.0K$631.0K
Total other comprehensive income$140.0K$393.0K$631.0K
Comprehensive loss-$141.1M-$122.1M-$89.0M

Compare Structure Therapeutics Inc. with another company

Leadership

Who has led Structure Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Raymond C. Stevens2023–now

Chief financial officer

  1. Jun Yoon2023–now

Chief operating officer

  1. Matthew Lang2026–now
2025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorChen Ming Yu named Oct 21, 2021 to Jan 10, 202225
  • DirectorCuiping Gu named Oct 21, 2021 to Jan 10, 202225
  • DirectorDaniel Auerbach named Oct 21, 2021 to Jan 10, 202225
  • DirectorJessica Lifton named Oct 21, 2021 to Jan 10, 202225
  • DirectorRobert Weisskoff named Oct 21, 2021 to Jan 10, 202225
  • DirectorTing Xie named Oct 21, 2021 to Jan 10, 202225

Former names

  • ShouTi Inc.Oct 21, 2021 to May 13, 20222

Timeline

  1. Feb 2, 2023New chief executive Raymond C. Stevens becomes CEO9

Filings

270 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 36 major events, 115 insider forms, 39 large holders, 4 private raises, 59 other. The latest 20:

  1. Sep 22, 20264 EDGAR
  2. Sep 21, 2026144 EDGAR
  3. Sep 8, 20268-K EDGAR
  4. Sep 2, 20264 EDGAR
  5. Aug 19, 20264 EDGAR
  6. Aug 7, 20264 EDGAR
  7. Aug 7, 20263 EDGAR
  8. Aug 6, 202610-Q EDGAR
  9. Aug 6, 20268-K EDGAR
  10. Aug 6, 2026SCHEDULE 13G/A EDGAR
  11. Aug 5, 20264 EDGAR
  12. Jul 24, 20264 EDGAR
  13. Jul 15, 20264 EDGAR
  14. Jun 29, 20264 EDGAR
  15. Jun 25, 2026144 EDGAR
  16. Jun 18, 20264 EDGAR
  17. Jun 18, 20264 EDGAR
  18. Jun 18, 20264 EDGAR
  19. Jun 18, 20264 EDGAR
  20. Jun 18, 20264 EDGAR

The 270 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 15, 2021Raised $7 million in a private offering of equity Form D: 8 investors so far Form D
  2. Jul 30, 2021Raised $100 million in a private offering of equity Form D: 30 investors so far Form D
  3. Mar 11, 2020Raised $26 million in a private offering of equity Form D: 9 investors so far Form D
  4. Apr 29, 2019Raised $32 million in a private offering of equity Form D: 6 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC7,810,306$419.2M0.0%−593,143
Wellington Management Group Llp7,379,433$396.1M0.1%+119,146
Avoro Capital Advisors LLC6,555,555$351.8M3.2%No change
Jupiter Topco LLC5,204,212$279.3M0.1%New
Deep Track Capital, LP4,740,072$254.4M3.7%+460,224
Bvf Inc/il3,366,823$180.7M4.6%−92,535
Morgan Stanley2,806,640$150.6M0.0%+501,183
Orbimed Advisors LLC2,209,400$118.6M2.3%+733,997
Principal Financial Group Inc1,752,753$94.1M0.0%−1,011
American Century Companies Inc1,682,179$90.3M0.0%+244,148
Rtw Investments, LP1,607,507$86.3M0.7%New
Driehaus Capital Management LLC1,553,219$83.4M0.5%−24,137
Baker Bros. Advisors LP1,432,529$76.9M0.4%No change
Casdin Capital, LLC1,175,000$63.1M3.2%No change
Deerfield Management Company, L.P.1,086,000$58.3M0.7%+318,007
Capitolis Liquid Global Markets LLC1,041,100$55.9M0.2%−110,200
Siren, L.L.C.872,967$46.9M1.0%−455,731
Pacific Heights Asset Management LLC800,000$42.9M1.4%+50,000
Rock Springs Capital Management LP640,317$34.4M1.7%+100
Aberdeen Group plc639,915$34.3M0.0%+248,106
Franklin Resources Inc578,839$31.1M0.0%+47,244
Bank Of America Corp /de/563,422$30.2M0.0%+336,290
Alliancebernstein L.P.611,708$29.5M0.0%−27,105
BlackRock, Inc.511,149$27.4M0.0%+69,174
Logos Global Management LP500,000$26.8M1.2%No change

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Oct 4, 2023Thomas R Carper, SenateSale$1,001 - $15,000+141.1%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34